Popovic MM, Nichani P, Muni RH, et al. - Researchers conducted a systematic search of Ovid MEDLINE, EMBASE and Cochrane CENTRAL (2005-2019) to examine the effectiveness and safety of intravitreal injection (IVI) of anti-vascular endothelial growth factor agents and laser photocoagulation (LPC) for retinopathy of prematurity (ROP). Comparative studies reporting on ocular effectiveness and/or safety outcomes following IVIs and LPC for ROP were involved. Twenty-four articles were involved, with 1,289 eyes receiving IVI and 2,412 eyes undergoing LPC. No differences were noted in visual and safety outcomes between IVI and LPC. LPC was less likely to undergo further therapy, while IVIs were associated with a longer interval from treatment to retreatment or recurrence, decreased risk of surgical intervention and superior refractive outcomes. All other outcomes were similar between IVIs and LPC.